) and partner
Regeneron Pharmaceuticals, Inc.
) announced positive results from a phase IIb study (n=380) on
dupilumab. Dupilumab is being developed for the treatment of adults
suffering from moderate-to-severe atopic dermatitis (AD), who
failed topical medication or for whom topical treatment is not
The phase IIb study randomized these patients to receive one of
five doses of dupilumab (300 mg weekly, 300 mg every other week,
300 mg monthly, 200 mg every other week, 100 mg monthly) or
placebo. Results revealed that the candidate (at all dosages
groups) successfully met its primary endpoint of a superior
improvement in mean percentage change in Eczema Area and Severity
Index (EASI) scores from baseline in comparison to placebo.
Moreover, a higher percentage of patients treated with dupilumab
achieved a clearing or near-clearing of skin lesions compared to
those under placebo. Also patients under dupilumab treatment arms
experienced a 16.5% to 47% mean reduction in itching compared to an
increase of 5% in patients under placebo.
Sanofi mentioned in its press release that the results will help
them to select the optimal doses of the candidate for the phase III
studies, which are expected to start later in the year.
Sanofi also announced that results from four placebo-controlled
studies including two phase IIa studies and two phase I studies on
dupilumab were published at the New England Journal of Medicine.
Sanofi, a large-cap pharma stock, carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the same sector include
Johnson & Johnson
). Both these stocks hold a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research?
Today, you can download 7 Best Stocks for the Next 30 Days.
Click to get this free report
REGENERON PHARM (REGN): Free Stock Analysis
SANOFI-AVENTIS (SNY): Free Stock Analysis
ASTRAZENECA PLC (AZN): Free Stock Analysis
JOHNSON & JOHNS (JNJ): Free Stock Analysis
To read this article on Zacks.com click here.